Citadel Advisors’s Loxo Oncology, Inc LOXO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
Sell
-15,800
Closed -$2.21M 10302
2018
Q4
$2.21M Sell
15,800
-4,200
-21% -$638K ﹤0.01% 3991
2018
Q3
$3.42M Sell
20,000
-14,900
-43% -$2.5M ﹤0.01% 3531
2018
Q2
$6.05M Buy
34,900
+11,000
+46% +$1.65M ﹤0.01% 2516
2018
Q1
$2.76M Buy
23,900
+16,400
+219% +$1.74M ﹤0.01% 3248
2017
Q4
$631K Sell
7,500
-1,100
-13% -$91.7K ﹤0.01% 5327
2017
Q3
$792K Buy
+8,600
New +$668K ﹤0.01% 4637

Other funds holding LOXO

Citadel Advisors's LOXO Position: Q1 2019 in Review

Citadel Advisors sold out of Loxo Oncology, Inc (LOXO) in Q1 2019, closing a stake of 4,902 shares — an estimated $686K sold.

Citadel Advisors first reported a position in LOXO in Q4 2015 and held it in 8 quarters. The position peaked at $3.71M in Q2 2018. 1 fund tracked by Wall St. Rank holds LOXO as of Q1 2019.

  • Citadel Advisors reported no remaining Loxo Oncology, Inc position as of Q1 2019 after selling out during the quarter.
  • Citadel Advisors sold 4,902 Loxo Oncology, Inc shares in Q1 2019, an estimated $686K.
  • Citadel Advisors first reported a position in Loxo Oncology, Inc in Q4 2015 and held it in 8 quarters.
  • Citadel Advisors's Loxo Oncology, Inc position peaked at $3.71M in Q2 2018.
  • 1 fund tracked by Wall St. Rank held Loxo Oncology, Inc as of Q1 2019.

Based on Citadel Advisors's 13F filing for Q1 2019, filed 15 May 2019.